Clinical trials: Coinfection, HIV
Visceral Leishmaniasis
Asymptomatic Leishmania Infection in HIV Patients
To collect pilot data on the prevalence and incidence of asymptomatic Leishmania donovani infection in HIV infected individuals in a visceral leishmaniasis (VL)-HIV endemic region to inform the feasibility of a larger study…
- Trial name
- NCT02839603
- Where
- Ethiopia
- Volunteers
- 540 people
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infection, Hepatitis C
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV).
- Trial name
- NCT01423643
- Where
- United States
- Volunteers
- 1,250 people
- Sponsor
- Johns Hopkins University
HIV, Hepatitis B
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina.
- Conditions
- HIV, Hepatitis B, Hepatitis C, AIDS
- Trial name
- EuroSIDA (NCT02699736)
- Where
- 110 sites in Argentina, Austria and 34 more
- Volunteers
- 23,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HCV HIV
Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
Background: Treatment for Hepatitis C has changed a lot in the past 2 years. Most of this change comes from a combination of medicines that is yielding high cure rates. But its long-term effects are uncertain.
- Trial name
- NCT02339038
- Testing
- Ledipasvir 90 mg and Sofosbuvir 400 mg
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections, Hepatitis C
Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
The purpose of this study is to compare how safe, tolerable, and effective a novel drug, raltegravir, is to a commonly used combination, atazanavir/ritonavir, as initial treatment in HIV/Hepatitis C co-infected injecting drug…
- Trial name
- NCT01105611
- Testing
- Raltegravir, Atazanavir/Ritonavir
- Where
- 2 sites in Ireland
- Volunteers
- 40 people
- Sponsor
- St. James's Hospital, Ireland
Hepatitis C Infection
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
The main questions being addressed are (1) how patient reported outcomes change during treatment for HCV, (2) how treatment impacts liver function and liver status, and (3) how much treatment costs from the payer's perspective…
- Trial name
- NCT02427204
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV, Tuberculosis
Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly
To describe the pharmacokinetics of rifabutin 150 mg once daily versus rifabutin 300 mg thrice weekly in combination with LPV/r 400/100mg based HAART in HIV/TB infected patients
- Trial name
- NCT02415985
- Testing
- Lopinavir/r will be supplied by NHSO/GPO, Rifabutin
- Where
- 4 sites in Thailand
- Volunteers
- 40 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Human Immunodeficiency Virus (HIV) Infection
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis
SaDAPT is a pragmatic, randomized, therapeutic-use trial comparing two approaches ("ART first" versus "TB results first") for the timing of ART initiation in PLHIV with presumptive TB, but no signs of central nervous system (CNS)…
- Trial name
- SaDAPT (NCT05452616)
- Testing
- ART first- Therapeutic use trial, TB results first- Therapeutic use trial
- Where
- 2 sites in Lesotho, Malawi
- Volunteers
- 610 people
- Sponsor
- University Hospital, Basel, Switzerland
HIV
HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients
New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population.
- Trial name
- ViDyMoCo (NCT02836782)
- Testing
- Blood sample withdrawal
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Catholic University of the Sacred Heart
HBV Coinfection, HIV Infections
Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients
In this pilot study, the investigators would examine the safety and efficacy of integrase inhibitor-Raltegravir in the control of HIV/HBV co-infection.
- Trial name
- NCT01318096
- Testing
- raltegravir and tenofovir and lamivudine, efavirenz+tenofovir+lamivudine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yunnan AIDS Care Center
Liver Cirrhosis
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.
- Trial name
- NCT06144086
- Testing
- Foscenvivint
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Kiminori Kimura, MD
Hiv, HBV Coinfection
Towards a Functional Cure for HBV - The COMMIT Cohort Study
Hepatitis B virus (HBV) infection can be treated, but therapy is usually lifelong and has side effects, so a cure for HBV is a critical endpoint.
- Trial name
- COMMIT (NCT03645044)
- Where
- 3 sites in India, Malaysia and 1 more
- Volunteers
- 102 people
- Sponsor
- University of Melbourne
Hepatitis C, HIV
NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection
The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV (Pegylated Interferon and Ribavirin)-induced anemia In HCV(hepatitis C virus)/HIV…
- Conditions
- Hepatitis C, HIV, Anemia
- Trial name
- NCT00315432
- Testing
- Pegylated Interferon and Ribavirin
- Volunteers
- 91 people
- Sponsor
- Ortho Biotech Products, L.P.
Chronic Hepatitis C
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both…
- Trial name
- INSIGHT (NCT01513941)
- Testing
- Telaprevir, Ribavirin, Pegylated-Interferon-alfa-2a
- Where
- 31 sites in Australia, Brazil and 6 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
HIV Infections, HIV-HBV Co-Infection
HIV-HBV Co-Infection and Liver Disease
Human immunodeficiency virus/Hepatitis B virus (HIV/HBV) co-infections are frequently observed due to shared routes of transmission, with reported figures indicating 6-9% of HIV-infected individuals in developed countries are…
- Trial name
- NCT00637429
- Where
- Australia
- Volunteers
- 70 people
- Sponsor
- Bayside Health
Human Immunodeficiency Virus (HIV), Tuberculosis
Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub-Saharan Africa.
- Conditions
- Human Immunodeficiency Virus (HIV), Tuberculosis, Coinfection
- Trial name
- NCT03800394
- Testing
- Observational PK study
- Where
- Ghana
- Volunteers
- 52 people
- Sponsor
- University of Florida
HIV Infections, Hepatitis B
Prospective Cohort of HIV/HBV-coinfected Patients in Europe
The overall aim of the project is to establish an international multi-cohort research platform of HIV/HBV-coinfected individuals treated with tenofovir to improve our understanding of the determinants of treatment outcomes.
- Conditions
- HIV Infections, Hepatitis B, Coinfection
- Trial name
- Euro-B (NCT04984772)
- Volunteers
- 1,107 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hepatitis B, Human Immunodeficiency Virus
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.
- Conditions
- Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
- Trial name
- NCT00782301
- Testing
- maraviroc, etravirine
- Where
- 18 sites in United States, Canada and 1 more
- Sponsor
- ViiV Healthcare
HIV
HIV Infection and Risk Related Coinfections/Comorbidities in Indonesia
INA-PROACTIVE is a multicenter, prospective, observational cohort study of HIV positive antiretroviral-naïve and treatment-experienced individuals. No investigational treatment or intervention will be used by this study.
- Trial name
- INAPROACTIVE (NCT03663920)
- Where
- 19 sites in Indonesia
- Volunteers
- 4,336 people
- Sponsor
- Ina-Respond
HIV Coinfection, Malaria
Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals
Optimal is a Randomized clinical trial to optimize treatment of malaria in HIV -malaria co infected patients. It has been demonstrated that, when the antimalarial drug Artemether Lumefantrine is co administered with Efavirenz…
- Trial name
- OPTIMAL (NCT04708496)
- Testing
- Artemether-lumefantrine
- Where
- 2 sites in Uganda
- Volunteers
- 888 people
- Sponsor
- Makerere University